Internship

2025 Co-Op

INT Distribution

Posted on 10/16/2024

Moderna

Moderna

5,001-10,000 employees

Develops mRNA-based medicines for health

Biotechnology
Healthcare

Norwood, MA, USA

Spring co-op opportunity from January 21st, 2025 – June 20, 2025. Must be available for the entire duration.

Category
Supply Chain Management
Transportation & Distribution
Warehouse Operations
Operations & Logistics
Required Skills
Supply Chain Management
Data Science
Requirements
  • Pursuing a B.S., M.S. or Ph.D. in Mechanical or Industrial Engineering
  • Ability to demonstrate academic or real-world examples of completed AI/automation/optimization projects
  • Good academic knowledge of supply chain management concepts
  • Strong knowledge of data science methods, specifically ANNs
  • Strong Operational Research knowledge, including mathematical optimization methods
  • Good knowledge of statistical methods
  • Knowledge of data pipeline, storage and visualization technologies is a plus
  • Good knowledge of Microsoft productivity tools
Responsibilities
  • Learn about the Moderna INT product and clinical trials portfolio
  • Understand the end-to-end process from manufacturing and testing to distribution and patient impact
  • Learn the “day-in-the-life” of a Distribution Planner
  • Support the building of basic database and Excel tools to gather and analyze operational data
  • Support the development and implementation of a comprehensive Distribution metrics framework (descriptive, diagnostic)
  • Analyze existing processes and systems to identify process and technology improvements
  • Use your leading-edge knowledge in processes and technologies to build AI, automation and optimization solutions to enable the vision of an end-to-end intelligent platform that does not require any manual transaction effort
  • Establish new processes for AI/automation/optimization model/engine maintenance by identifying how and when the models/engines are out of control and need retraining

Moderna focuses on developing medicines using messenger RNA (mRNA), which is a crucial component in how cells produce proteins necessary for various biological functions. Their approach involves creating a new class of medicines that utilize mRNA to instruct cells to produce specific proteins, potentially leading to significant advancements in treating diseases. Unlike traditional pharmaceuticals, which often rely on small molecules or proteins, Moderna's mRNA-based therapies aim to enhance the speed and efficiency of drug discovery and manufacturing. The company's goal is to improve patient outcomes by harnessing the power of mRNA to create effective treatments for a range of health conditions.

Company Stage

IPO

Total Funding

$5.9B

Headquarters

Cambridge, Massachusetts

Founded

2010

Growth & Insights
Headcount

6 month growth

4%

1 year growth

15%

2 year growth

48%
Simplify Jobs

Simplify's Take

What believers are saying

  • Moderna's AI-driven drug discovery accelerates novel mRNA-based therapeutics identification.
  • Expansion in Asia enhances global supply chain and reduces production costs.
  • mRNA technology is gaining traction for non-infectious disease vaccines, like cancer.

What critics are saying

  • Potential Nasdaq 100 removal could impact stock visibility and investor interest.
  • Bypassing safety steps in Australia may raise regulatory and public scrutiny concerns.
  • Hong Kong's reluctance to receive Covid-19 jab affects market penetration and sales.

What makes Moderna unique

  • Moderna is pioneering mRNA technology for a new class of medicines.
  • The company focuses on mRNA's potential to transform drug discovery and manufacturing.
  • Moderna's mRNA platform enables rapid development of vaccines and therapeutics.

Help us improve and share your feedback! Did you find this helpful?

INACTIVE